{
    "ticker": "AGEN",
    "name": "Agenus Inc.",
    "description": "Agenus Inc. is a biotechnology company focused on developing innovative immuno-oncology therapies to treat cancer. Founded in 1994, the company is dedicated to harnessing the power of the immune system to combat tumors and improve patient outcomes. Agenus has built a diverse portfolio of drug candidates, including immune checkpoint inhibitors, cancer vaccines, and monoclonal antibodies aimed at enhancing the body\u2019s immune response to cancer. The company's lead product candidates, such as AGEN1181, target key immune checkpoints to restore anti-tumor activity. In addition to its core therapeutic offerings, Agenus is also engaged in advancing its proprietary technologies, including its advanced adjuvant platform and a range of next-generation antibody products. With a collaborative approach, Agenus partners with other biopharmaceutical companies and academic institutions to accelerate the development and commercialization of its therapies. The company\u2019s mission is to transform the treatment of cancer and provide hope to patients through groundbreaking science, a commitment to research, and a focus on patient-centered care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Lexington, Massachusetts, USA",
    "founded": "1994",
    "website": "https://www.agenusbio.com",
    "ceo": "Garo H. Armen",
    "social_media": {
        "twitter": "https://twitter.com/AgenusInc",
        "linkedin": "https://www.linkedin.com/company/agenus/"
    },
    "investor_relations": "https://investors.agenusbio.com",
    "key_executives": [
        {
            "name": "Garo H. Armen",
            "position": "CEO"
        },
        {
            "name": "Jennifer J. Baird",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immuno-Oncology Therapies",
            "products": [
                "AGEN1181",
                "AGEN2034"
            ]
        },
        {
            "category": "Cancer Vaccines",
            "products": [
                "QS-21"
            ]
        }
    ],
    "seo": {
        "meta_title": "Agenus Inc. | Innovative Immuno-Oncology Therapies",
        "meta_description": "Explore Agenus Inc., a leader in immuno-oncology committed to developing innovative therapies for cancer treatment. Learn about our groundbreaking research and pipeline.",
        "keywords": [
            "Agenus",
            "Immuno-Oncology",
            "Cancer Therapies",
            "Biotechnology",
            "Cancer Vaccines",
            "AGEN1181",
            "AGEN2034"
        ]
    },
    "faq": [
        {
            "question": "What is Agenus known for?",
            "answer": "Agenus is known for developing innovative immuno-oncology therapies to treat cancer."
        },
        {
            "question": "Who is the CEO of Agenus?",
            "answer": "Garo H. Armen is the CEO of Agenus Inc."
        },
        {
            "question": "Where is Agenus headquartered?",
            "answer": "Agenus is headquartered in Lexington, Massachusetts, USA."
        },
        {
            "question": "What are Agenus's main products?",
            "answer": "Agenus's main products include AGEN1181, AGEN2034, and QS-21."
        },
        {
            "question": "When was Agenus founded?",
            "answer": "Agenus was founded in 1994."
        }
    ],
    "competitors": [
        "BMY",
        "MRNA",
        "REGN",
        "NVAX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "CELG"
    ]
}